Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form PTO/SB/08a & PTO/SB/08b FOURTH INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)						Application Number Filing Date First Named Inventor Art Unit Examiner Name		mplete if Known 10/594,427 July 17, 2008 Masashi Isozaki et al. 1633 James Schultz				
Sheet		1 of 1			Attorney Docket Number			1029650-000178				
					DATENTO	COUNTRIES						
Examiner Initials'	Cite No. ¹	Cite Document Number Publ No.1 Number-Kind Code ² (if known)		Publica MM-DI			f Patentee or Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
				EODEIG	N DATEN	T DOCUMENTS						
	FOREIGN PATENT DOCUMENTS											
Examiner Initials'	Cite No.1 Country Code ³ Number ⁴ Kind Code ⁵ (if known)		Publication Date Applicant of MM-DD-YYYY Docume		nt of C	Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T				
NON PATENT LITERATURE DOCUMENTS												
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.										
			Bioimaging, Stealth Liposomes: Local Chemotherapy (2008), http://www.bioimaging.dk/index.php?id=75, printed on January 19, 2012									
		Wan-Liang Lu et al., A Pegylated Liposomal Platform: Pharmacokinetics, Pharmacodynamics, and Toxicity in Mice Using Doxorubicin as a Model Drug, 95 J. PHARMACOL SCI 381-389 (2004)										

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.